Clinical Trial

A Study to Investigate the Effect of Food on the Bioavailability of Oral Paclitaxel Administered With Encequidar in Participants With Advanced Solid Tumors

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to learn about the effect of food on absorption of oral Paclitaxel when co- administered with Encequidar tablets in adult patients with tumours. The main questions it aims to answer are: * The effect of food and fasting on absorption of oral paclitaxel when combined with Encequidar tablets * Assessment of safety and tolerability of oral paclitaxel when combined with Encequidar tablets Participants will take Encequidar and oral paclitaxcel with a 1-hour space in between, either after an overnight fast of 10hours or after a meal three days in a row. After 10 days participants that received paclitaxel after fasting will receive the same medicine in the same way after a meal and vice versa. Some participants can elect to take part in the third part of the study which involves taking both paclitaxel and encequidar at the same time after a meal. Participants will \- For parts 1,2 and 3 participants will stay at the clinic from the day before the study starts until day 4 to receive the medicine and participate in checkups and tests. Participants will then visit the clinic on day 6 and 8 for further checkups and tests
Trial Details
NCT Number NCT07580833
Lead Sponsor Health Hope Pharma
Conditions Metastatic Breast Cancer
Enrollment 46 participants
Start Date 2026-05
Primary Completion 2026-12 (estimated)
Study Completion 2027-03 (estimated)
Updated on ClinicalTrials.gov 2026-05-12